journal article·2018-11-12Open access

Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes

Armin Mooranian, Nassim Zamani, Ryu Takechi, Hesham Al-Sallami, Momir Mikov, Svetlana Goločorbin-Kon, Bozica Kovacevic, Frank Arfuso, Hani Al-Salami

Abstract

INTRODUCTION: The ratio of secondary to primary bile acids changes during Type 1 Diabetes (T1D) development and these effects might be ameliorated by using cholesterol lowering drugs or hydrophilic bile acids. Probucol is a cholesterol-lowering drug, while ursodeoxycholic acid is a hydrophilic bile acid. This study investigated whether nanoencapsulated probucol with ursodeoxycholic acid altered bile acid ratios and the development of diabetes. METHODS: Balb/c mice were divided into three groups and gavaged daily with either free probucol, nanoencapsulated probucol or nanoencapsulated probucol with ursodeoxycholic acid for seven days. Alloxan was injected and once T1D was confirmed the mice continued to receive daily gavages until euthanasia. Blood, tissues, faeces and urine were collected for analysis of insulin and bile acids. RESULTS AND CONCLUSIONS: Nanoencapsulated probucol-ursodeoxycholic acid resulted in significant levels of insulin in the blood, lower levels of secondary bile acids in liver and lower levels of primary bile acids in brain, while ratio of secondary to primary bile acids remains similar among all groups, except in the faeces. Findings suggests that nanoencapsulated probucol-ursodeoxycholic acid may exert a protective effect on pancreatic β-cells and reserve systemic insulin load via modulation of bile acid concentrations in the liver and brain.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Pancreatic function and diabetes · Drug Transport and Resistance Mechanisms · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University

School of Public Health, Curtin Health Innovation Research Institute, Curtin University

School of Pharmacy, University of Otago

Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad

Department of Pharmacy, University of Novi Sad

Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University

Funding

Beijing Nat-Med Biotechnology Co. Ltd. · University, State and Commonwealth Governments · European Union Horizon 2020

References (30)

Show source-provided references
1. Negrulj R, Mooranian A, Al-Salami H. Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system. J Endocrinol Diabetes. 2013;1:49–59.
2. 10.1007/s13346-015-0248-910.1007/s13346-015-0248-9 ↗
3. 10.1016/j.ejps.2017.05.04110.1016/j.ejps.2017.05.041 ↗
4. Kirkpatrick RB, Kraft BG. Effect of streptozotocin-induced diabetes on bile acid sulfation in male rat liver. Am J Physiol. 1984;247:G226–G230.
5. 10.2337/diab.32.10.90010.2337/diab.32.10.900 ↗
6. 10.1016/0006-2944(84)90021-810.1016/0006-2944(84)90021-8 ↗
7. 10.1079/BJN1994001210.1079/BJN19940012 ↗
8. 10.1111/nmo.1209410.1111/nmo.12094 ↗
9. 10.1002/jcb.2609710.1002/jcb.26097 ↗
10. 10.1002/jcb.2617410.1002/jcb.26174 ↗
11. 10.1186/s12929-016-0303-y10.1186/s12929-016-0303-y ↗
12. 10.1016/j.toxlet.2014.04.00110.1016/j.toxlet.2014.04.001 ↗
13. 10.1159/00028209110.1159/000282091 ↗
14. 10.1016/j.metabol.2011.10.02310.1016/j.metabol.2011.10.023 ↗
15. 10.1016/j.bbalip.2014.04.00810.1016/j.bbalip.2014.04.008 ↗
16. 10.3109/10837450.2014.99978510.3109/10837450.2014.999785 ↗
17. 10.3389/fnagi.2017.0039910.3389/fnagi.2017.00399 ↗
18. 10.3109/21691401.2015.106929910.3109/21691401.2015.1069299 ↗
19. 10.1208/s12249-014-0205-910.1208/s12249-014-0205-9 ↗
20. 10.1007/s13346-017-0473-510.1007/s13346-017-0473-5 ↗
21. 10.2147/DDDT.S6734910.2147/DDDT.S67349 ↗
22. 10.1358/mf.2008.30.2.115965210.1358/mf.2008.30.2.1159652 ↗
23. 10.1007/s13318-011-0060-y10.1007/s13318-011-0060-y ↗
24. 10.1007/BF0319138310.1007/BF03191383 ↗
25. 10.1006/bbrc.1995.159010.1006/bbrc.1995.1590 ↗
26. 10.1016/S1056-8719(99)00019-210.1016/S1056-8719(99)00019-2 ↗
27. 10.1007/978-1-4899-0405-8_610.1007/978-1-4899-0405-8_6 ↗
28. 10.1080/0163558980951468910.1080/01635589809514689 ↗
29. 10.1097/MIB.000000000000087910.1097/MIB.0000000000000879 ↗
30. 10.1016/0016-5085(80)90912-910.1016/0016-5085(80)90912-9 ↗